Kendell Clement

Kendell Clement is a leading researcher in biomedical informatics and genome editing, with expertise in CRISPR technology, epigenetics, and hematopoietic stem cell research. Current affiliations include collaborative work in cancer genomics and computational biology.

Education:

• PhD, Harvard-MIT Program in Health Sciences and Technology
• BS, Brigham Young University

Research focuses on optimizing CRISPR-based gene editing to evade genotoxicity, developing tools like CRISPResso2 and CRISPR-SURF, and exploring epigenetic mechanisms in cancers such as multiple myeloma and chronic lymphocytic leukemia. Recent work includes in vivo modeling, single-cell analysis, and novel base editing platforms for immune cell engineering.

Key trends in publications (2010–2025) span genome editing specificity, epigenetic regulation in stem cells, and cancer evolutionary dynamics. Notable contributions include patents on cancer diagnostics and therapies, as well as methods for DNA methylation profiling.

Collaborative Networks:

• Massachusetts General Hospital (Postdoctoral Fellowship)
• Harvard-MIT Program (Doctoral Training)
• Free University (Fellowship)